An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis用于对抗结核分枝杆菌的基于RNA的疫苗平台VACCINESIF3.42023-01-0536OAAI
Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulationsFRONTIERS IN MICROBIOLOGYIF4.52022-08-269OAAI
Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse modelsSCIENTIFIC REPORTSIF3.92021-04-2717OAAI
Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29ANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52019-12-0149OAAI
Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy TreatmentVACCINESIF3.42018-05-2422OAAI
Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of TuberculosisJOURNAL OF INFECTIOUS DISEASESIF4.52015-01-3030OAAI
Immune Subdominant Antigens as Vaccine Candidates against Mycobacterium tuberculosisJOURNAL OF IMMUNOLOGYIF3.42014-09-1539OAAI
Chitin Microneedles for an Easy-to-Use Tuberculosis Skin TestADVANCED HEALTHCARE MATERIALSIF9.62013-08-2656PREAI
Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic TreatmentJOURNAL OF INFECTIOUS DISEASESIF4.52012-08-1394OA
The Importance of Adjuvant Formulation in the Development of a Tuberculosis VaccineJOURNAL OF IMMUNOLOGYIF3.42012-03-01113OAAI
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl proteinJOURNAL OF IMMUNOTHERAPYIF2.91998-07-0122PREAI